,2 As vascular endothelial growth factor (VEGF) is the primary mediator of macular edema and retinal angiogenesis,3–5 anti-VEGF agents, such as aflibercept, bevacizumab, and ranibizumab, have been used in treatments for CRVO-associated macular edema. Here, VEGFA is linked to macular retinal edema.